Theseus Pharmaceuticals, Inc. Common Stock
THRX
THRX was delisted on the 13th of February, 2024.
63 hedge funds and large institutions have $95.5M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 15 closing their positions.
10% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 21
9% less funds holding
Funds holding: 69 → 63 (-6)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
74% less capital invested
Capital invested by funds: $374M → $95.5M (-$278M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.23M |
| 2 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$2.05M |
| 3 |
O
OrbiMed
New York
|
+$1.88M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.02M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$629K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$18.2M |
| 2 |
DM
Deerfield Management
New York
|
-$13.1M |
| 3 |
VA
VR Adviser
New York
|
-$7.18M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$5.93M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.64M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIM
76
MetLife Investment Management
Whippany,
New Jersey
| – | -$96.4K | -10,330 | Closed |
|
|
MLICM
77
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$10.5K | -1,126 | Closed |
|
78
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1.52K | -163 | Closed |
|
THRX Hedge Fund Activity: Q3 2023 in Review
63 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q3 2023, worth a combined $95.5M — down 74% from $374M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of THRX and 10 opened new positions — a net loss of 5 holders — while 21 trimmed existing stakes and 19 added.
The largest buyer was Millennium Management, adding an estimated $6.23M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $18.2M sold.
- 63 institutional investors held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q3 2023, down from 69 in Q2 2023.
- Funds reported $95.5M of Theseus Pharmaceuticals, Inc. Common Stock stock for Q3 2023, down 74% quarter-over-quarter.
- 10 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q3 2023 and 15 closed out, a net change of -5 holders.
- The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q3 2023 was Millennium Management, an estimated $6.23M added.
- The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q3 2023 was Paradigm Biocapital Advisors, an estimated $18.2M sold.
Based on aggregated 13F filings for Q3 2023.